Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients

CONCLUSIONS: While SG dosed concurrently with talazoparib is not tolerated clinically due to an insufficient therapeutic window, sequential dosing of SG then talazoparib proved a viable strategy. These findings support further clinical development of the combination and suggest that ADC-based therapy may facilitate novel, mechanism-based dosing strategies.PMID:38709212 | DOI:10.1158/1078-0432.CCR-24-0428

Source: Clinical Cancer Research - May 6, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Sheng Sun Nayana Thimmiah James T Coates Bogang Wu Rachel O Abelman Laura Spring Beverly Moy Phoebe Ryan Mark N Melkonyan Ann Partridge Dejan Juric Jeffrey Peppercorn Heather Parsons Seth A Wander Victoria Attaya Brenda Lormil Maria Shellock Source Type: research